[关于使用0.75%布比卡因的争议]
[Controversies regarding the use of 0.75% bupivacaine].
作者信息
Knapik P, Gallert G, Knapik M, Antoszewski Z
机构信息
Zakładu Anastezjologii i Intensywnej Terapii Górniczego Centrum Medycznego, Katowicach.
出版信息
Wiad Lek. 1992 Jul;45(13-14):523-6.
Controversies are described regarding wide introduction of bupivacaine with raised concentration (0.75%) of the active components, which has been introduced in other countries in the strongest local anaesthetic agent used as yet but in early 1980s it has been withdrawn from several western countries in view of possible serious cardiovascular side effects. Presently, after a number of studies it been demonstrated that these suppositions were unfounded and the observed complication were due errors in anaesthesiological techniques and not to an exceptional cardiotoxicity of the drug.
关于广泛引入活性成分浓度提高（0.75%）的布比卡因存在争议，这种布比卡因在其他国家已作为迄今最强效的局部麻醉剂引入，但在20世纪80年代初，鉴于可能存在的严重心血管副作用，它已在几个西方国家被停用。目前，经过多项研究表明，这些推测是没有根据的，观察到的并发症是由于麻醉技术失误，而非该药物特殊的心脏毒性。
Zotero 插件